3-hydroxybutyric acid has been researched along with Seizures in 50 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neither KD treatment nor pioglitazone alone or in combination affected clonic seizures." | 7.85 | Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. ( Matthews, SA; Simeone, KA; Simeone, TA, 2017) |
| " Seizure threshold was tested by intravenous infusion of pentylenetetrazole (PTZ) whereas seizure severity was determined from measuring the hindlimb extension to flexion (E/F) ratio after seizures were evoked by maximal electroshock stimulation (MES)." | 7.70 | A ketogenic diet has different effects upon seizures induced by maximal electroshock and by pentylenetetrazole infusion. ( Bough, KJ; Eagles, DA; Matthews, PJ, 2000) |
| "The purpose of this study was to test the hypothesis that a ketogenic diet would increase the resistance of rats to pentylenetetrazole (PTZ)-induced seizures and to understand the relation of ketonemia to seizure resistance." | 7.70 | A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat. ( Bough, KJ; Eagles, DA, 1999) |
| "The role of BHB in diminishing OS and seizure might be more remarkable than ARA." | 5.91 | The effects of ketogenic diet on beta-hydroxybutyrate, arachidonic acid, and oxidative stress in pediatric epilepsy. ( Afghan, M; Barzegar, M; Golchinfar, Z; Poorshiri, B; Raeisi, S; Shahabi, P; Shiva, S; Yousefi Nodeh, HR, 2023) |
| "Epileptic seizures have been shown to stimulate the proliferation rate of neuronal progenitor cells in adult animals, which may be related to epileptogenesis." | 5.35 | Effects of the ketogenic diet on neurogenesis after kainic acid-induced seizures in mice. ( Choi, ES; Jeong, SW; Kim, DW; Kwon, YS; Son, BK, 2008) |
| "Short-term MAD was associated with metabolic differences in plasma and resected epilepsy brain tissue when compared to control participants, in combination with trending expression changes observed in hippocampal NADH-related signaling pathways." | 4.31 | Metabolomic, proteomic, and transcriptomic changes in adults with epilepsy on modified Atkins diet. ( Devinsky, O; Devore, S; Friedman, D; Jones, DR; Kanshin, E; Korman, A; Leitner, DF; Lin, Z; Siu, Y; Tsirigos, A; Ueberheide, B; Wisniewski, T, 2023) |
| "Neither KD treatment nor pioglitazone alone or in combination affected clonic seizures." | 3.85 | Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. ( Matthews, SA; Simeone, KA; Simeone, TA, 2017) |
| "This study was designed to investigate the effects of β-hydroxybutyrate (BHB) on pilocarpine-induced seizures in young mice." | 3.78 | β-Hydroxybutyrate increases the pilocarpine-induced seizure threshold in young mice. ( Kim, DW; Ko, TS; Yum, MS, 2012) |
| "We evaluated the ability of the ketogenic diet (KD) to improve thresholds to flurothyl-induced seizures in two mouse lines with Scn1a mutations: one that models Dravet syndrome (DS) and another that models genetic (generalized) epilepsy with febrile seizures plus (GEFS+)." | 3.77 | Protective effect of the ketogenic diet in Scn1a mutant mice. ( Borges, K; Catterall, WA; Dutton, SB; Escayg, A; Jumbo-Lucioni, P; Kalume, F; Sawyer, NT, 2011) |
| " Seizures were induced by the volatile convulsant agent flurothyl." | 3.77 | Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats. ( Khazipov, R; Minlebaev, M, 2011) |
| " Seizures were induced by the 6 Hz test, kainic acid, maximal electroshock, or pentylenetetrazol." | 3.76 | Seizure tests distinguish intermittent fasting from the ketogenic diet. ( Bergbower, E; Hardwick, JM; Hartman, AL; Kennedy, M; Zheng, X, 2010) |
| " Seizures were induced by timed infusion of pentylenetetrazole (PTZ) and maximal electroshock (MES)." | 3.71 | Comparison of the anticonvulsant efficacies and neurotoxic effects of valproic acid, phenytoin, and the ketogenic diet. ( Bough, KJ; Eagles, DA, 2001) |
| " Seizure threshold was tested by intravenous infusion of pentylenetetrazole (PTZ) whereas seizure severity was determined from measuring the hindlimb extension to flexion (E/F) ratio after seizures were evoked by maximal electroshock stimulation (MES)." | 3.70 | A ketogenic diet has different effects upon seizures induced by maximal electroshock and by pentylenetetrazole infusion. ( Bough, KJ; Eagles, DA; Matthews, PJ, 2000) |
| " Results also showed that the animals fed calorie-restricted high-fat diets exhibited significant ketonemia and protection from pentylenetetrazole (PTZ)-induced seizures." | 3.70 | Higher ketogenic diet ratios confer protection from seizures without neurotoxicity. ( Bough, KJ; Eagles, DA; Yao, SG, 2000) |
| "The present study was designed to evaluate the effects of age on the efficacy of the ketogenic diet in suppressing seizures evoked by tail-vein infusion of pentylenetetrazole (PTZ)." | 3.70 | Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet. ( Bough, KJ; Eagles, DA; Han, FT; Valiyil, R, 1999) |
| "The purpose of this study was to test the hypothesis that a ketogenic diet would increase the resistance of rats to pentylenetetrazole (PTZ)-induced seizures and to understand the relation of ketonemia to seizure resistance." | 3.70 | A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat. ( Bough, KJ; Eagles, DA, 1999) |
| "The role of BHB in diminishing OS and seizure might be more remarkable than ARA." | 1.91 | The effects of ketogenic diet on beta-hydroxybutyrate, arachidonic acid, and oxidative stress in pediatric epilepsy. ( Afghan, M; Barzegar, M; Golchinfar, Z; Poorshiri, B; Raeisi, S; Shahabi, P; Shiva, S; Yousefi Nodeh, HR, 2023) |
| "Epilepsy is a chronic neurological disorder that affects approximately 50 million people worldwide." | 1.46 | Reduction of epileptiform activity in ketogenic mice: The role of monocarboxylate transporters. ( Becker, HM; Deitmer, JW; Forero-Quintero, LS, 2017) |
| "The time of first seizure onset in group 1 was 109." | 1.43 | Fasting time duration modulates the onset of insulin-induced hypoglycemic seizures in mice. ( Afrin, MR; Arumugam, S; Harima, M; Karuppagounder, V; Miyashita, S; Nakamura, M; Nakamura, T; Pitchaimani, V; Sreedhar, R; Suzuki, H; Suzuki, K; Thandavarayan, RA; Ueno, K; Watanabe, K, 2016) |
| "The mechanism responsible for the anti-seizure effect of ketogenic diets is poorly understood." | 1.43 | Ketogenic diet prevents neuronal firing increase within the substantia nigra during pentylenetetrazole-induced seizure in rats. ( Coppola, G; Iovane, V; Monda, M; Operto, FF; Pisano, S; Stoddard, M; Viggiano, A, 2016) |
| "PTZ) seizure tests in mice." | 1.42 | Acute anticonvulsant effects of capric acid in seizure tests in mice. ( Czuczwar, SJ; Gasior, M; Nieoczym, D; Socała, K; Wlaź, P; Żarnowska, I; Żarnowski, T, 2015) |
| "The only seizure test where short-term rapamycin treatment protected mice was against tonic hindlimb extension in the MES threshold test, though this protection waned with longer rapamycin treatment." | 1.38 | The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice. ( Dolce, A; Hardwick, JM; Hartman, AL; Santos, P, 2012) |
| "The ketogenic diet (KD) is a treatment of infantile spasms (IS)." | 1.37 | The relationship of ketosis and growth to the efficacy of the ketogenic diet in infantile spasms. ( Chu-Shore, CJ; Numis, AL; Pfeifer, HH; Thiele, EA; Yellen, MB, 2011) |
| "Rats fed a KD had a higher seizure threshold (longer latency to flurothyl-induced seizure activity) than rats fed a standard diet (SD); this effect was seen when KD was in place at the time of seizure testing (3 and 6 weeks following FPI), but was absent when KD had been replaced by SD at time of testing." | 1.36 | Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury? ( Campos, L; Delance, A; Lyeth, BG; Nguyen, DV; Poon, CC; Schwartzkroin, PA; Van, KC; Wenzel, HJ, 2010) |
| "KA tests." | 1.36 | Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose. ( French, A; Gasior, M; Hartman, AL; Rogawski, MA; Yankura, J, 2010) |
| "However, chronic in vitro ketosis abolished hippocampal network hyperexcitability following a metabolic insult, hypoxia, demonstrating for the first time a direct link between metabolic resistance and better control of excessive, synchronous, abnormal electrical activity." | 1.36 | Chronic in vitro ketosis is neuroprotective but not anti-convulsant. ( Abdelmalik, P; Carlen, PL; Samoilova, M; Velumian, AA; Weisspapir, M, 2010) |
| "We compared the degree of ketosis with seizure reduction." | 1.36 | Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. ( Hulsman, J; Lambrechts, D; Majoie, M; van Delft, R; Verschuure, P, 2010) |
| "Epileptic seizures have been shown to stimulate the proliferation rate of neuronal progenitor cells in adult animals, which may be related to epileptogenesis." | 1.35 | Effects of the ketogenic diet on neurogenesis after kainic acid-induced seizures in mice. ( Choi, ES; Jeong, SW; Kim, DW; Kwon, YS; Son, BK, 2008) |
| "The behavior in four mouse seizure models, plasma d-beta-hydroxybutyrate (d-BHB) and glucose levels were determined after feeding control diet, 4:1 and 6:1 KDs with matched vitamins, minerals and antioxidants." | 1.35 | Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. ( Borges, K; Samala, R; Willis, S, 2008) |
| ""Threshold doses" and "latency to seizure" data provided conflicting measures of seizure threshold." | 1.33 | A comparison of the ability of a 4:1 ketogenic diet and a 6.3:1 ketogenic diet to elevate seizure thresholds in adult and young rats. ( Abdelmalik, PA; Burnham, WM; Clarke, J; Likhodii, S; Nylen, K, 2005) |
| "Acetone has been shown to have broad-spectrum anticonvulsant actions in animal seizure models and has been hypothesized to play a role in the anticonvulsant mechanism of the ketogenic diet (KD)." | 1.33 | A ketogenic diet and diallyl sulfide do not elevate afterdischarge thresholds in adult kindled rats. ( Burnham, WM; Hum, KM; Likhodii, SS; Nylen, K, 2006) |
| "During seizures, ATP and PCr values declined significantly below their homologous controls." | 1.31 | Prolonged neonatal seizures exacerbate hypoxic-ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release. ( Armstrong, EA; Miyashita, H; Wirrell, EC; Yager, JY, 2002) |
| "In fact, the tests involving maximal seizures actually showed proconvulsant effects." | 1.31 | The MCT ketogenic diet: effects on animal seizure models. ( Burnham, WM; Cunnane, SC; Dell, C; Iracleous, C; Likhodii, SS; Mendonca, A; Musa, K; Thavendiranathan, P, 2000) |
| "To understand how ketosis and seizure protection are related, a reliable, noninvasive measure of ketosis that can be performed frequently with minimal discomfort is needed." | 1.31 | Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals. ( Cunnane, SC; Likhodii, SS; Musa-Veloso, K, 2002) |
| "Results indicate that seizure threshold was significantly elevated with increasing ketogenic ratios (i." | 1.30 | Path analysis shows that increasing ketogenic ratio, but not beta-hydroxybutyrate, elevates seizure threshold in the Rat. ( Bough, KJ; Chen, RS; Eagles, DA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.00) | 18.7374 |
| 1990's | 5 (10.00) | 18.2507 |
| 2000's | 17 (34.00) | 29.6817 |
| 2010's | 21 (42.00) | 24.3611 |
| 2020's | 5 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janicot, R | 1 |
| Shao, LR | 1 |
| Stafstrom, CE | 1 |
| De La Rossa, A | 1 |
| Laporte, MH | 1 |
| Astori, S | 1 |
| Marissal, T | 1 |
| Montessuit, S | 1 |
| Sheshadri, P | 1 |
| Ramos-Fernández, E | 1 |
| Mendez, P | 1 |
| Khani, A | 1 |
| Quairiaux, C | 1 |
| Taylor, EB | 1 |
| Rutter, J | 1 |
| Nunes, JM | 1 |
| Carleton, A | 1 |
| Duchen, MR | 1 |
| Sandi, C | 1 |
| Martinou, JC | 1 |
| Osuch, B | 1 |
| Kołosowska, K | 1 |
| Chmielewska, N | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Szyndler, J | 1 |
| Maciejak, P | 1 |
| Poorshiri, B | 1 |
| Barzegar, M | 1 |
| Afghan, M | 1 |
| Shiva, S | 1 |
| Shahabi, P | 1 |
| Golchinfar, Z | 1 |
| Yousefi Nodeh, HR | 1 |
| Raeisi, S | 1 |
| Leitner, DF | 1 |
| Siu, Y | 1 |
| Korman, A | 1 |
| Lin, Z | 1 |
| Kanshin, E | 1 |
| Friedman, D | 1 |
| Devore, S | 1 |
| Ueberheide, B | 1 |
| Tsirigos, A | 1 |
| Jones, DR | 1 |
| Wisniewski, T | 1 |
| Devinsky, O | 1 |
| Li, J | 1 |
| O'Leary, EI | 1 |
| Tanner, GR | 1 |
| Simeone, TA | 1 |
| Matthews, SA | 1 |
| Simeone, KA | 1 |
| Forero-Quintero, LS | 1 |
| Deitmer, JW | 1 |
| Becker, HM | 1 |
| Meidenbauer, JJ | 1 |
| Roberts, MF | 1 |
| Wlaź, P | 2 |
| Socała, K | 2 |
| Nieoczym, D | 2 |
| Żarnowski, T | 1 |
| Żarnowska, I | 1 |
| Czuczwar, SJ | 1 |
| Gasior, M | 2 |
| Pieróg, M | 1 |
| Law, TH | 1 |
| Davies, ES | 1 |
| Pan, Y | 1 |
| Zanghi, B | 1 |
| Want, E | 1 |
| Volk, HA | 1 |
| Yum, MS | 2 |
| Lee, M | 1 |
| Woo, DC | 1 |
| Kim, DW | 5 |
| Ko, TS | 2 |
| Velíšek, L | 1 |
| Viggiano, A | 1 |
| Stoddard, M | 1 |
| Pisano, S | 1 |
| Operto, FF | 1 |
| Iovane, V | 1 |
| Monda, M | 1 |
| Coppola, G | 1 |
| Pitchaimani, V | 1 |
| Arumugam, S | 1 |
| Thandavarayan, RA | 1 |
| Karuppagounder, V | 1 |
| Afrin, MR | 1 |
| Sreedhar, R | 1 |
| Harima, M | 1 |
| Suzuki, H | 1 |
| Miyashita, S | 1 |
| Nakamura, T | 1 |
| Suzuki, K | 1 |
| Nakamura, M | 1 |
| Ueno, K | 1 |
| Watanabe, K | 1 |
| Tan, KN | 1 |
| Carrasco-Pozo, C | 1 |
| McDonald, TS | 1 |
| Puchowicz, M | 1 |
| Borges, K | 3 |
| Samala, R | 1 |
| Willis, S | 1 |
| van Delft, R | 1 |
| Lambrechts, D | 1 |
| Verschuure, P | 1 |
| Hulsman, J | 1 |
| Majoie, M | 1 |
| Samoilova, M | 1 |
| Weisspapir, M | 1 |
| Abdelmalik, P | 1 |
| Velumian, AA | 1 |
| Carlen, PL | 1 |
| Hartman, AL | 3 |
| Zheng, X | 1 |
| Bergbower, E | 1 |
| Kennedy, M | 1 |
| Hardwick, JM | 2 |
| Yankura, J | 1 |
| French, A | 1 |
| Rogawski, MA | 1 |
| Schwartzkroin, PA | 2 |
| Wenzel, HJ | 1 |
| Lyeth, BG | 1 |
| Poon, CC | 1 |
| Delance, A | 1 |
| Van, KC | 1 |
| Campos, L | 1 |
| Nguyen, DV | 1 |
| Minlebaev, M | 1 |
| Khazipov, R | 1 |
| Numis, AL | 1 |
| Yellen, MB | 1 |
| Chu-Shore, CJ | 1 |
| Pfeifer, HH | 1 |
| Thiele, EA | 1 |
| Dutton, SB | 1 |
| Sawyer, NT | 1 |
| Kalume, F | 1 |
| Jumbo-Lucioni, P | 1 |
| Catterall, WA | 1 |
| Escayg, A | 1 |
| Santos, P | 1 |
| Dolce, A | 1 |
| Bough, KJ | 7 |
| Gudi, K | 1 |
| Han, FT | 2 |
| Rathod, AH | 1 |
| Eagles, DA | 8 |
| Yager, JY | 1 |
| Armstrong, EA | 1 |
| Miyashita, H | 1 |
| Wirrell, EC | 1 |
| Boyd, SJ | 1 |
| Kotak, A | 1 |
| Allan, F | 1 |
| Tabb, K | 1 |
| Szot, P | 1 |
| White, SS | 1 |
| Liles, LC | 1 |
| Weinshenker, D | 1 |
| Nylen, K | 2 |
| Likhodii, S | 1 |
| Abdelmalik, PA | 1 |
| Clarke, J | 1 |
| Burnham, WM | 3 |
| Noh, HS | 1 |
| Cho, GJ | 1 |
| Choi, WS | 1 |
| Kang, SS | 1 |
| Likhodii, SS | 3 |
| Hum, KM | 1 |
| Hallböök, T | 1 |
| Köhler, S | 1 |
| Rosén, I | 1 |
| Lundgren, J | 1 |
| Kwon, YS | 1 |
| Jeong, SW | 1 |
| Choi, ES | 1 |
| Son, BK | 1 |
| Schreiber, RA | 1 |
| Ungar, AL | 1 |
| Nakazawa, M | 1 |
| Kodama, S | 1 |
| Matsuo, T | 1 |
| Valiyil, R | 1 |
| Chavko, M | 1 |
| Braisted, JC | 1 |
| Harabin, AL | 1 |
| Chen, RS | 1 |
| Rho, JM | 1 |
| Robbins, CA | 1 |
| Anderson, GD | 1 |
| Yao, SG | 1 |
| Matthews, PJ | 1 |
| Thavendiranathan, P | 1 |
| Mendonca, A | 1 |
| Dell, C | 1 |
| Musa, K | 1 |
| Iracleous, C | 1 |
| Cunnane, SC | 2 |
| Gilbert, DL | 1 |
| Pyzik, PL | 1 |
| Freeman, JM | 1 |
| Harney, JP | 1 |
| Madara, J | 2 |
| I'Anson, H | 1 |
| Musa-Veloso, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)[NCT02036853] | Phase 2 | 20 participants (Actual) | Interventional | 2014-02-20 | Completed | ||
| Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome[NCT05469997] | 50 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| Efficacy of Exogenous Ketone Esters for Children With Refractory Convulsive Status Epileptics[NCT05674552] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| Efficacy of Ketone Esters for Children With Drug Resistant Epilepsy[NCT05670847] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| Characterization of a Portable Solid-State Breath Acetone Testing Device for Real-Time Ketosis Status and Comparison to Blood Ketone Testing[NCT04130724] | 21 participants (Actual) | Observational | 2019-10-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and four yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -8.3 |
| Schedule B | -80.3 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and five yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | 23 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and one yr
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -6.5 |
| Schedule B | -110.5 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. (NCT02036853)
Timeframe: Baseline and 13 weeks
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | 4.4 |
| Schedule B | 189.5 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and 18 months
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -5.8 |
| Schedule B | -112.7 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and two yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -6 |
| Schedule B | -61.25 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and 26 weeks
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -5.6 |
| Schedule B | -78 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and three yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -0.8 |
| Schedule B | -77 |
1 trial available for 3-hydroxybutyric acid and Seizures
| Article | Year |
|---|---|
A randomised trial of a medium-chain TAG diet as treatment for dogs with idiopathic epilepsy.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Blood Glucose; Bromides; Cross-Over Studies; Diet, | 2015 |
49 other studies available for 3-hydroxybutyric acid and Seizures
| Article | Year |
|---|---|
2-deoxyglucose and β-hydroxybutyrate fail to attenuate seizures in the betamethasone-NMDA model of infantile spasms.
Topics: 3-Hydroxybutyric Acid; Adrenocorticotropic Hormone; Animals; Animals, Newborn; Betamethasone; Deoxyg | 2022 |
Paradoxical neuronal hyperexcitability in a mouse model of mitochondrial pyruvate import deficiency.
Topics: 3-Hydroxybutyric Acid; Animals; Anion Transport Proteins; Biological Transport; Calcium; Gene Expres | 2022 |
Increased Hippocampal Afterdischarge Threshold in Ketogenic Diet is Accompanied by Enhanced Kynurenine Pathway Activity.
Topics: 3-Hydroxybutyric Acid; Amino Acids, Branched-Chain; Animals; Diet, Ketogenic; Hippocampus; Kynurenin | 2022 |
The effects of ketogenic diet on beta-hydroxybutyrate, arachidonic acid, and oxidative stress in pediatric epilepsy.
Topics: 3-Hydroxybutyric Acid; Arachidonic Acid; Child; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; | 2023 |
Metabolomic, proteomic, and transcriptomic changes in adults with epilepsy on modified Atkins diet.
Topics: 3-Hydroxybutyric Acid; Adult; Diet, Carbohydrate-Restricted; Diet, High-Protein Low-Carbohydrate; Di | 2023 |
The ketogenic diet metabolite beta-hydroxybutyrate (β-HB) reduces incidence of seizure-like activity (SLA) in a K
Topics: 3-Hydroxybutyric Acid; Animals; Animals, Genetically Modified; Anticonvulsants; Disease Models, Anim | 2017 |
Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Body Weight; Convulsants; Diet, Ketogenic; Disease Mo | 2017 |
Reduction of epileptiform activity in ketogenic mice: The role of monocarboxylate transporters.
Topics: 3-Hydroxybutyric Acid; Animals; Astrocytes; Brain; Diet, Ketogenic; Disease Models, Animal; Epilepsy | 2017 |
Reduced glucose utilization underlies seizure protection with dietary therapy in epileptic EL mice.
Topics: 3-Hydroxybutyric Acid; Animals; Brain; Caloric Restriction; Diet, Ketogenic; Disease Models, Animal; | 2014 |
Acute anticonvulsant effects of capric acid in seizure tests in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Blood Glucose; Brain; Caprylates; Decanoic Acids; D | 2015 |
Role of the adenosine system and glucose restriction in the acute anticonvulsant effect of caprylic acid in the 6 Hz psychomotor seizure test in mice.
Topics: 3-Hydroxybutyric Acid; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonis | 2015 |
β-Hydroxybutyrate attenuates NMDA-induced spasms in rats with evidence of neuronal stabilization on MR spectroscopy.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Brain; Disease Models, Animal; Humans; Infant, Newb | 2015 |
Ketogenic diet prevents neuronal firing increase within the substantia nigra during pentylenetetrazole-induced seizure in rats.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Animals; Blood Glucose; Body Weight; Convulsants; Diet, Ke | 2016 |
Fasting time duration modulates the onset of insulin-induced hypoglycemic seizures in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Disease Models, Animal; Fasting; Hypoglycemia; Infusi | 2016 |
Tridecanoin is anticonvulsant, antioxidant, and improves mitochondrial function.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Antioxidants; Blood Glucose; Brain; Decanoates; Dis | 2017 |
Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models.
Topics: 3-Hydroxybutyric Acid; Analysis of Variance; Animals; Antioxidants; Blood Glucose; Body Weight; Conv | 2008 |
Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Child; Child, Preschool; Diet, Ketogenic; Female; Follow-U | 2010 |
Chronic in vitro ketosis is neuroprotective but not anti-convulsant.
Topics: 3-Hydroxybutyric Acid; Animals; Animals, Newborn; Cytoprotection; Diet, Ketogenic; Disease Models, A | 2010 |
Seizure tests distinguish intermittent fasting from the ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Analysis of Variance; Animals; Anticonvulsants; Blood Glucose; Caloric Restri | 2010 |
Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose.
Topics: 3-Hydroxybutyric Acid; Analysis of Variance; Animals; Anticonvulsants; Antimetabolites; Blood Glucos | 2010 |
Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury?
Topics: 3-Hydroxybutyric Acid; Animals; Brain Injuries; CD11b Antigen; Cell Count; Cell Death; Diet, Ketogen | 2010 |
Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats.
Topics: 3-Hydroxybutyric Acid; Animals; Animals, Suckling; Anticonvulsants; Brain; Bumetanide; Convulsants; | 2011 |
The relationship of ketosis and growth to the efficacy of the ketogenic diet in infantile spasms.
Topics: 3-Hydroxybutyric Acid; Anthropometry; Blood Glucose; Body Height; Body Weight; Cohort Studies; Diet, | 2011 |
β-Hydroxybutyrate increases the pilocarpine-induced seizure threshold in young mice.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Convulsants; Diet, Ketogenic; Ketone Bodies; Male; | 2012 |
Protective effect of the ketogenic diet in Scn1a mutant mice.
Topics: 3-Hydroxybutyric Acid; Animals; Convulsants; Diet, Ketogenic; Disease Models, Animal; Dose-Response | 2011 |
The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Animals; Anticonvulsants; Blood Glucose; Blotting, Western; Ce | 2012 |
An anticonvulsant profile of the ketogenic diet in the rat.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Bicuculline; Convulsants; Dietary Fats; Disease Mod | 2002 |
Prolonged neonatal seizures exacerbate hypoxic-ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release.
Topics: 3-Hydroxybutyric Acid; Adenosine Triphosphate; Animals; Animals, Newborn; Blood Glucose; Excitatory | 2002 |
Calorie restriction of a high-carbohydrate diet elevates the threshold of PTZ-induced seizures to values equal to those seen with a ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Animals; Body Weight; Convulsants; Dietary Carbohydrates; Dietary Fats; Energ | 2003 |
The ketogenic diet does not alter brain expression of orexigenic neuropeptides.
Topics: 3-Hydroxybutyric Acid; Animals; Brain Chemistry; Eating; Energy Metabolism; Epilepsy; Galanin; In Si | 2004 |
A comparison of the ability of a 4:1 ketogenic diet and a 6.3:1 ketogenic diet to elevate seizure thresholds in adult and young rats.
Topics: 3-Hydroxybutyric Acid; Age Factors; Animals; Blood Glucose; Body Weight; Dietary Fats; Disease Model | 2005 |
Increased nitric oxide caused by the ketogenic diet reduces the onset time of kainic acid-induced seizures in ICR mice.
Topics: 3-Hydroxybutyric Acid; Animal Feed; Animals; Anticonvulsants; Diet; Immunohistochemistry; Kainic Aci | 2006 |
A ketogenic diet and diallyl sulfide do not elevate afterdischarge thresholds in adult kindled rats.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Allyl Compounds; Analysis of Variance; Animals; Antic | 2006 |
Effects of ketogenic diet on epileptiform activity in children with therapy resistant epilepsy.
Topics: 3-Hydroxybutyric Acid; Adolescent; Attention; Child; Child, Preschool; Data Interpretation, Statisti | 2007 |
Effects of the ketogenic diet on neurogenesis after kainic acid-induced seizures in mice.
Topics: 3-Hydroxybutyric Acid; Animals; Antimetabolites; Bromodeoxyuridine; Cell Proliferation; Convulsants; | 2008 |
Temporal changes in liver, blood, and brain glucose, glycogen, and beta-hydroxybutyrate after ethanol in C57BL/6J mice.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Brain; Ethanol; Glycogen; Hydroxybutyrates; Liver; Li | 1984 |
Effects of ketogenic diet on electroconvulsive threshold and brain contents of adenosine nucleotides.
Topics: 3-Hydroxybutyric Acid; Adenine Nucleotides; Animals; Brain Chemistry; Diet; Dietary Fats; Electric S | 1983 |
A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat.
Topics: 3-Hydroxybutyric Acid; Animals; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Epileps | 1999 |
Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Aging; Animals; Behavior, Animal; Convulsants; Diet; Energy Intake; Growth; K | 1999 |
Attenuation of brain hyperbaric oxygen toxicity by fasting is not related to ketosis.
Topics: 3-Hydroxybutyric Acid; Animals; Biomarkers; Blood Glucose; Butylene Glycols; Electroencephalography; | 1999 |
Path analysis shows that increasing ketogenic ratio, but not beta-hydroxybutyrate, elevates seizure threshold in the Rat.
Topics: 3-Hydroxybutyric Acid; Aging; Animals; Body Weight; Convulsants; Diet; Differential Threshold; Disea | 1999 |
Age-dependent differences in flurothyl seizure sensitivity in mice treated with a ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Age Factors; Animals; Convulsants; Flurothyl; Humans; Ketone Bodies; Ketosis; | 1999 |
Higher ketogenic diet ratios confer protection from seizures without neurotoxicity.
Topics: 3-Hydroxybutyric Acid; Animals; Basal Metabolism; Behavior, Animal; Convulsants; Diet; Dietary Fats; | 2000 |
A ketogenic diet has different effects upon seizures induced by maximal electroshock and by pentylenetetrazole infusion.
Topics: 3-Hydroxybutyric Acid; Animals; Biomarkers; Convulsants; Diet, Reducing; Dietary Fats; Electroshock; | 2000 |
The MCT ketogenic diet: effects on animal seizure models.
Topics: 3-Hydroxybutyric Acid; Animal Feed; Animals; Body Weight; Dietary Fats, Unsaturated; Electroshock; M | 2000 |
The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Child; Cost-Benefit Analysis; Dietary Fats; Dietary Proteins; Fas | 2000 |
The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Child; Cost-Benefit Analysis; Dietary Fats; Dietary Proteins; Fas | 2000 |
The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Child; Cost-Benefit Analysis; Dietary Fats; Dietary Proteins; Fas | 2000 |
The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Child; Cost-Benefit Analysis; Dietary Fats; Dietary Proteins; Fas | 2000 |
Comparison of the anticonvulsant efficacies and neurotoxic effects of valproic acid, phenytoin, and the ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Animals; Anticonvulsants; Dietary Fats; Electroencephalography; Energy Intake | 2001 |
Effects of acute inhibition of fatty acid oxidation on latency to seizure and concentrations of beta hydroxybutyrate in plasma of rats maintained on calorie restriction and/or the ketogenic diet.
Topics: 3-Hydroxybutyric Acid; Animals; Caloric Restriction; Diet; Dietary Fats; Fatty Acids; Ketosis; Male; | 2002 |
Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Breath Tests; Diet; Dietary Fats; Epilepsy; Fa | 2002 |